Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity but Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 2, 2016, Pages 404-411

  Ronsein, Graziella E ^a   Hutchins, Patrick M ^a   Isquith, Daniel ^a   Vaisar, Tomas ^a   Zhao, Xue Qiao ^a   Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

atherosclerosis; cardiovascular diseases; macrophages; niacin; triglycerides

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; ABCA1 PROTEIN, HUMAN; CHOLESTEROL; DRUG COMBINATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BHK CELL LINE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL EFFLUX CAPACITY; CONTROLLED STUDY; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CAROTID ARTERY DISEASES; CELL LINE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; MIDDLE AGED; MOUSE; TIME FACTOR; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ANIMALS; ATORVASTATIN CALCIUM; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL TRANSPORT; CAROTID ARTERY DISEASES; CELL LINE; CHOLESTEROL; CHOLESTEROL, HDL; CRICETINAE; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MALE; MICE; MIDDLE AGED; NIACIN; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84955635473     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306268     Document Type: Article

References (41)

1. Gordon DJ, Rifkind BM, High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989 321 1311 1316. doi: 10.1056/NEJM198911093211907.
2. Rader DJ, Tall AR, The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012 18 1344 1346. doi: 10.1038/nm.2937.
3. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797.
4. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New Engl J Med 2011s 365 2255 2267
5. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010 30 796 801
6. Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Asztalos BF, Bittman R, Rothblat GH, A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid Res 2011 52 2332 2340. doi: 10.1194/jlr.D018051.
7. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011 364 127 135. doi: 10.1056/NEJMoa1001689.
8. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT, Wareham N, Rader DJ, Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 2015 3 507 513. doi: 10.1016/S2213-8587(15)00126-6.
9. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW, HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014 371 2383 2393. doi: 10.1056/NEJMoa1409065.
10. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ, HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011 57 392 410. doi: 10.1373/clinchem.2010.155333.
11. Vaisar T, Pennathur S, Green PS, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007 117 746 756. doi: 10.1172/JCI26206.
12. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W, HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 2015 116 1133 1142. doi: 10.1161/CIRCRESAHA.116.305485.
13. Phillips MC, Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 2014 289 24020 24029. doi: 10.1074/jbc.R114.583658.
14. Kontush A, Lhomme M, Chapman MJ, Unraveling the complexities of the HDL lipidome. J Lipid Res 2013 54 2950 2963. doi: 10.1194/jlr.R036095.
15. Davidson WS, HDL-C vs HDL-P: how changing one letter could make a difference in understanding the role of high-density lipoprotein in disease. Clin Chem 2014 60 e1 e3. doi: 10.1373/clinchem.2014.232769.
16. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE, Krauss RM, Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 2008 54 1307 1316. doi: 10.1373/clinchem.2007.100586.
17. Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y, Anantharamaiah GM, Kim DS, Ranchalis JE, Jarvik GP, Vaisar T, Heinecke JW, Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem 2014 60 1393 1401. doi: 10.1373/clinchem.2014.228114.
18. Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW, Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. J Am Heart Assoc 2013 2 e000037. doi: 10.1161/JAHA.113.000037.
19. Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP, Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy. Am Heart J 2009 157 687.e1 687.e8. doi: 10.1016/j.ahj.2009.01.001.
20. Jafri H, Alsheikh-Ali AA, Mooney P, Kimmelstiel CD, Karas RH, Kuvin JT, Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol 2009 3 45 50. doi: 10.1016/j.jacl.2008.12.003.
21. Khera AV, Patel PJ, Reilly MP, Rader DJ, The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 2013 62 1909 1910. doi: 10.1016/j.jacc.2013.07.025.
22. Zhao XQ, Phan BA, Chu B, Bray F, Moore AB, Polissar NL, Dodge JT Jr, Lee CD, Hatsukami TS, Yuan C, Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J 2007 154 239 246. doi: 10.1016/j.ahj.2007.04.035.
23. Sniderman A, Vu H, Cianflone K, Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991 89 109 116
24. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR, AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009 55 407 419. doi: 10.1373/clinchem.2008.118356.
25. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010 30 1430 1438. doi: 10.1161/ATVBAHA.110.207142.
26. Vaughan AM, Oram JF, ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 2003 44 1373 1380. doi: 10.1194/jlr.M300078-JLR200.
27. Oram JF, Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1. Trends Mol Med 2002 8 168 173
28. Oram JF, Heinecke JW, ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005 85 1343 1372. doi: 10.1152/physrev.00005.2005.
29. Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K, Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol 2014 34 2246 2253. doi: 10.1161/ATVBAHA.114.303715.
30. Miyamoto-Sasaki M, Yasuda T, Monguchi T, Nakajima H, Mori K, Toh R, Ishida T, Hirata K, Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb 2013 20 708 716
31. Mora S, Glynn RJ, Ridker PM, High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013 128 1189 1197. doi: 10.1161/CIRCULATIONAHA.113.002671.
32. Otvos JD, The surprising AIM-HIGH results are not surprising when viewed through a particle lens. J Clin Lipidol 2011 5 368 370. doi: 10.1016/j.jacl.2011.06.012.
33. El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM, High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 2009 150 84 93
34. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S, High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012 60 508 516. doi: 10.1016/j.jacc.2012.03.060.
35. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006 113 1556 1563. doi: 10.1161/CIRCULATIONAHA.105.565135.
36. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R, Heart Protection Study Collaborative Group Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012 125 2469 2478. doi: 10.1161/CIRCULATIONAHA.111.073684.
37. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009 119 931 939. doi: 10.1161/CIRCULATIONAHA.108.816181.
38. Heinecke JW, Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL. Circ Res 2015 116 1101 1103. doi: 10.1161/CIRCRESAHA.115.306052.
39. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 1267 1278. doi: 10.1016/S0140-6736(05)67394-1.
40. Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ, Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol 2015 66 2201 2210. doi: 10.1016/j.jacc.2015.09.013.
41. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR, Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007 117 3900 3908. doi: 10.1172/JCI33372.